ATE363074T1 - Substrate und screeningverfahren für transportproteine - Google Patents

Substrate und screeningverfahren für transportproteine

Info

Publication number
ATE363074T1
ATE363074T1 AT00966735T AT00966735T ATE363074T1 AT E363074 T1 ATE363074 T1 AT E363074T1 AT 00966735 T AT00966735 T AT 00966735T AT 00966735 T AT00966735 T AT 00966735T AT E363074 T1 ATE363074 T1 AT E363074T1
Authority
AT
Austria
Prior art keywords
transport proteins
substrates
screening methods
methods
screening
Prior art date
Application number
AT00966735T
Other languages
English (en)
Inventor
William Dower
Mark Gallop
Ronald Barrett
Kenneth Cundy
Tania Chernov-Rogan
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Application granted granted Critical
Publication of ATE363074T1 publication Critical patent/ATE363074T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/081,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1086Preparation or screening of expression libraries, e.g. reporter assays
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT00966735T 1999-09-14 2000-09-14 Substrate und screeningverfahren für transportproteine ATE363074T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15407199P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
ATE363074T1 true ATE363074T1 (de) 2007-06-15

Family

ID=22549879

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00966735T ATE363074T1 (de) 1999-09-14 2000-09-14 Substrate und screeningverfahren für transportproteine

Country Status (6)

Country Link
US (2) US7413536B1 (de)
EP (1) EP1212619B1 (de)
AT (1) ATE363074T1 (de)
AU (1) AU7703400A (de)
DE (1) DE60034954D1 (de)
WO (1) WO2001020331A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405151A1 (en) * 2000-04-07 2001-10-18 University Of Maryland, Baltimore Bile acid containing prodrugs with enhanced bioavailability
PT1305329E (pt) 2000-08-05 2007-12-24 Glaxo Group Ltd Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-(2-furanilcarboxil)oxi-11.beta.-hidroxi-16.alfa.-metil- 3-oxo-androsta-1,4-dieno-17-carbotióico como um agente antiinflamatório
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
MY137522A (en) 2001-04-30 2009-02-27 Glaxo Group Ltd Novel anti-inflammatory androstane derivatives.
WO2002100344A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2002100172A1 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Administration of agents via the pept-2 transporter
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
NZ535354A (en) 2002-02-15 2008-01-31 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
WO2003102579A2 (fr) * 2002-05-31 2003-12-11 Commissariat A L'energie Atomique Methode de criblage de banques de molecules radioactives et ses applications
FR2840994B1 (fr) * 2003-01-22 2008-07-18 Commissariat Energie Atomique Methode de criblage de banques de biomolecules et ses applications
FR2840407B1 (fr) * 2002-05-31 2008-07-18 Commissariat Energie Atomique Methode de criblage de banques de biomolecules et ses applications
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
EP1567169A4 (de) 2002-11-04 2009-10-21 Xenoport Inc Gemcitabin-prodrugs, phramazeutische zusammensetzungen und verwendungen davon
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
WO2005075992A1 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Mct1 transporter expressed in blood brain barrier cells
US7910593B2 (en) * 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
WO2006017351A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
US7550506B2 (en) 2004-07-12 2009-06-23 Xenoport, Inc. Amino acid derived prodrugs of propofol, compositions and uses thereof
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
JP2009510198A (ja) * 2005-09-26 2009-03-12 インヴィトロジェン コーポレーション 紫色レーザー励起性色素及びその使用方法
CN101371137B (zh) * 2006-01-31 2013-03-27 塞诺菲-安万特股份有限公司 测定有机阳离子转运蛋白活性的方法
EP1991702A4 (de) * 2006-02-17 2009-04-22 Univ Leland Stanford Junior Sequenzielle reportergen-lumineszenz (srl)-verfahren und zusammensetzung zu ihrer ausführung
EP2011880B1 (de) 2006-04-13 2012-10-24 Chugai Seiyaku Kabushiki Kaisha Taurintransporter-gen
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
AU2007333225B2 (en) * 2006-12-08 2014-06-12 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
EP2135946B1 (de) 2007-03-15 2015-12-09 Chugai Seiyaku Kabushiki Kaisha Verfahren zur polypeptidherstellung
US8697397B2 (en) 2007-08-07 2014-04-15 Chugai Seiyaku Kabushiki Kaisha Method of producing heterogeneous protein
RU2486245C2 (ru) 2007-10-15 2013-06-27 Чугаи Сейяку Кабусики Кайся Способ получения клетки, способной продуцировать гетеропротеины с высоким выходом
CA2703493C (en) * 2007-10-24 2016-11-08 Chugai Seiyaku Kabushiki Kaisha A cell for use in production of heteroproteins and production method using the same
EP2276479B1 (de) 2008-04-15 2014-07-02 SineVir Therapeutics LLC Prodrugs von neuraminidasehemmern
JP2012517811A (ja) * 2009-02-13 2012-08-09 エックス−ボディ インコーポレイテッド Dnaディスプレイを利用した核酸送達ビヒクルの同定方法
EP3653763A1 (de) 2009-02-13 2020-05-20 X-Chem, Inc. Verfahren zur erstellung und durchsuchung von dna-codierten bibliotheken
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
US8367842B2 (en) * 2009-07-16 2013-02-05 Beckman Coulter, Inc. Fluorescent dyes and uses thereof
JP5561692B2 (ja) * 2010-03-09 2014-07-30 国立大学法人群馬大学 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法
EP4137137A1 (de) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
US8399262B2 (en) 2011-03-23 2013-03-19 Darrel A. Mazzari Biosensor
DK2748357T3 (en) 2011-09-07 2018-07-16 X Chem Inc Methods for labeling DNA-encoded libraries
SG10201909122QA (en) 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20140323412A1 (en) 2011-10-28 2014-10-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CA2879018A1 (en) 2012-07-13 2014-01-16 X-Chem, Inc. Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
KR20180084756A (ko) 2015-12-07 2018-07-25 지머젠 인코포레이티드 코리네박테리움 글루타미컴으로부터의 프로모터
JP2019519241A (ja) * 2016-06-30 2019-07-11 ザイマージェン インコーポレイテッド グルコース透過酵素ライブラリーを生成するための方法およびその使用
KR102345899B1 (ko) 2016-06-30 2021-12-31 지머젠 인코포레이티드 박테리아 헤모글로빈 라이브러리를 생성하는 방법 및 이의 용도
GB2552460A (en) * 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
JP7562546B2 (ja) 2019-02-12 2024-10-07 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞性肝疾患を有する小児対象の成長を増加させる方法
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
KR20220115927A (ko) 2019-10-25 2022-08-19 세르카코르 래버러토리즈, 인크. 지표 화합물, 지표 화합물을 포함하는 장치, 및 이의 제조 및 사용 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5569678A (en) * 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5866123A (en) 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
US5236902A (en) * 1990-11-26 1993-08-17 The Governors Of The University Of Alberta Method and probes for detecting nucleoside transporter and method for producing the probes
US5580775A (en) 1992-05-01 1996-12-03 Emory University High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4222315A1 (de) 1992-07-05 1994-01-13 Inst Genbiologische Forschung DNA-Sequenzen für Aminosäuretransporter, Plasmide, Bakterien, Hefen und Pflanzen enthaltend einen Transporter
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5658782A (en) 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
DE4343527A1 (de) 1993-12-16 1995-06-22 Schering Ag Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung
US5589358A (en) 1993-12-29 1996-12-31 Univ Wake Forest Ileal bile acid transporter compositions and methods
US5849525A (en) 1994-03-09 1998-12-15 Brigham And Women's Hospital, Inc. Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same
DE59505727D1 (de) * 1994-11-12 1999-05-27 Basf Ag Verfahren zur herstellung von aminen aus verbindungen mit mindestens 3 cyanogruppen
JPH11504218A (ja) * 1995-04-24 1999-04-20 クロマゾーム コーポレーション 新規代謝経路の生成およびスクリーニングのための方法
ES2299232T3 (es) 1995-09-11 2008-05-16 La Jolla Cancer Research Foundation Moleculas que migran hacia un organo o tejido seleccionado in vivo.
DE69629385T2 (de) * 1995-11-10 2004-06-09 Elan Corp. Plc Peptide, die den transport über gewebe erhöhen und verfahren zu ihrer identifizierung und verwendung
US5780264A (en) 1996-06-06 1998-07-14 The President And Fellows Of Harvard College Iron transport protein
EP0923603A1 (de) * 1996-07-16 1999-06-23 Novo Nordisk A/S Oligopeptid-transporter
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
DE69824174T2 (de) 1997-02-27 2005-07-14 Cellomics, Inc. Ein system zur zellbasierten reihenuntersuchung
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
JP4129298B2 (ja) 1997-05-15 2008-08-06 サイトジェン コーポレーション 胃腸管(git)輸送受容体に結合するランダムペプチド、及び関連した方法
CA2297413A1 (en) * 1997-07-15 1999-01-28 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents

Also Published As

Publication number Publication date
EP1212619A4 (de) 2004-12-08
US20090221442A1 (en) 2009-09-03
EP1212619A1 (de) 2002-06-12
EP1212619B1 (de) 2007-05-23
WO2001020331A9 (en) 2002-10-03
DE60034954D1 (de) 2007-07-05
US7413536B1 (en) 2008-08-19
AU7703400A (en) 2001-04-17
WO2001020331A1 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
ATE363074T1 (de) Substrate und screeningverfahren für transportproteine
DE60232688D1 (de) Grenzflächen-biomaterialien
NO20043245L (no) Bindingsproteiner som biosensorer
DE60226797D1 (de) Instrument zum Einbringen von Befestigungselementen für Transplantate
WO2007120699A3 (en) Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
DE69925276D1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
DE60137203D1 (de) Poröse ferro- oder ferrimagnetische glasteilchen für molekültrennung
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
DE60005787D1 (de) Wasserlösliche rhodaminfarbstoffe und ihre konjugate
ATE233762T1 (de) Bicyclische polyamiosaure metallkomplexe, verfahren zu ihrer herstellung und ihre verwendung für medizinische bilderzeugung
ATE352784T1 (de) Verfahren zum screenen für gpr40-liganden
ITRM980303A0 (it) Composizione contenente radioisotopi immobilizzati su particelle solide utile in particolare per la biancheria clinica in patologie
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
DE59806371D1 (de) Kontrastmittel für das infarkt- und nekroseimaging
WO1999050459A3 (en) High throughput in vitro screening assays for transcription modulators
DK1049721T3 (da) Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse
MXPA03011898A (es) Ensayo de seleccion in vitro para ?- secretasa.
WO2001008707A3 (de) Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen
ATE252574T1 (de) Benzofuran-2-ones als färbemittel für organische materialien
DE69913533D1 (de) Reagentien für cyp2d fluoreszenztest
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.
NO20025738D0 (no) Metode
DK1171444T3 (da) Pyridothienodiazepiner, fremgangsmåde til fremstilling af disse og farmaceutiske præparater indeholdende disse
DE60332076D1 (de) Doppelmessverfahren zur Anzeige des Inhalts von Poststücken

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties